© 2022 accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
Other projects funded by the HERA Incubator call for expressions of interest on coronavirus variants. The goal of these projects, along with COVend, is to boost COVID-19 prevention and treatment and further inform public health policy and clinical management.
ExeVir’s XVR011, a best in class nanobodybased biology that broadly neutralizes SARSCOV-1 and SARS-COV-2
Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC
Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anticytokine activity
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© 2022 accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy